← Back to Search

Local Anesthetic

Liposomal bupivacaine for Lumbar Spine Degeneration (Exparel Trial)

Phase 4
Waitlist Available
Led By Fassil Mesfin, MD, PhD
Research Sponsored by University of Missouri-Columbia
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up until final follow-up, up to 8 weeks.
Awards & highlights

Exparel Trial Summary

This trial will help determine if a local anesthetic can decrease the amount of opioids needed after surgery.

Exparel Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~until final follow-up, up to 8 weeks.
This trial's timeline: 3 weeks for screening, Varies for treatment, and until final follow-up, up to 8 weeks. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Postoperative Opioid Utilization
Secondary outcome measures
Length of Stay
Operative Data and Complications
Post Operative Pain Scores

Exparel Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: Liposomal bupivacaineActive Control1 Intervention
Patients in this group will be given the study drug (liposomal bupivacaine).
Group II: Placebo GroupPlacebo Group1 Intervention
Patients in this group will be given the placebo (sterile saline).

Find a Location

Who is running the clinical trial?

University of Missouri-ColumbiaLead Sponsor
361 Previous Clinical Trials
627,960 Total Patients Enrolled
1 Trials studying Lumbar Spine Degeneration
Fassil Mesfin, MD, PhDPrincipal InvestigatorUniversity of Missouri - Missouri Orthopaedic Institute
Theodore Choma, MDPrincipal InvestigatorUniversity of Missouri - Missouri Orthopaedic Institute
1 Previous Clinical Trials
9 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the maximum participant count for this clinical experiment?

"Affirmative. According to information on clinicaltrials.gov, this medical study, which was first made available on February 10th 2021, is actively recruiting patients. 200 volunteers need to be sourced from a single location for the trial's completion."

Answered by AI

Are there any vacancies still available in this clinical trial?

"As indicated on the clinicaltrials.gov site, recruitment for this trial is currently underway and was initiated on February 10th 2021. The information was most recently updated on October 20th 2021."

Answered by AI

In what instances is Liposomal bupivacaine typically prescribed?

"Liposomal bupivacaine is frequently prescribed for pemphigus and can be beneficial to those with acute nonspecific tenosynovitis, lupus erythematosus cell, and general anesthesia."

Answered by AI

Has the FDA sanctioned Liposomal bupivacaine for use?

"Considering its approval status, Liposomal bupivacaine was assigned a safety rating of 3 on the scale."

Answered by AI

Are there any other trials that have been conducted on Liposomal bupivacaine?

"Currently, there are 109 Liposomal bupivacaine studies in operation with 18 of them being at the Phase 3 stage. While Philadelphia Pennsylvania is home to many trials for this medication, 144 clinical sites across the country offer participation in a research trial."

Answered by AI
Recent research and studies
Plastic and Reconstructive Surgery - Global OpenJournal
Postoperative Pain and Length of Stay Lowered by Use of Exparel in Immediate, Implant-based Breast Reconstruction
Butz, Daniel R., Deana S. Shenaq, Veronica L. M. Rundell, Brittany Kepler, Eric Liederbach, Jeff Thiel, Catherine Pesce, Glenn S. Murphy, Mark Sisco, and Michael A. Howard. 2015. “Postoperative Pain and Length of Stay Lowered by Use of Exparel in Immediate, Implant-based Breast Reconstruction”. Plastic and Reconstructive Surgery - Global Open. Ovid Technologies (Wolters Kluwer Health). doi:10.1097/gox.0000000000000355.
Global Spine JournalJournal
Postoperative Pain Management After Spinal Fusion Surgery: An Analysis of the Efficacy of Continuous Infusion of Local Anesthetics
Reynolds, Richard A. K., Julie E. Legakis, Jillian Tweedie, YoungKey Chung, Emily J. Ren, Patricia A. BeVier, Ronald L. Thomas, and Suresh T. Thomas. 2013. “Postoperative Pain Management After Spinal Fusion Surgery: An Analysis of the Efficacy of Continuous Infusion of Local Anesthetics”. Global Spine Journal. SAGE Publications. doi:10.1055/s-0033-1337119.
AnesthesiologyJournal
Practice Guidelines for Acute Pain Management in the Perioperative Setting
“Practice Guidelines for Acute Pain Management in the Perioperative Setting”. 2012. “Practice Guidelines for Acute Pain Management in the Perioperative Setting”. Anesthesiology. Ovid Technologies (Wolters Kluwer Health). doi:10.1097/aln.0b013e31823c1030.
AnesthesiologyJournal
A Novel Liposomal Bupivacaine Formulation to Produce Ultralong-acting Analgesia
Grant, Gilbert J., Yechezkel Barenholz, Elijah M. Bolotin, Mylarrao Bansinath, Herman Turndorf, Boris Piskoun, and Elyad M. Davidson. 2004. “A Novel Liposomal Bupivacaine Formulation to Produce Ultralong-acting Analgesia”. Anesthesiology. Ovid Technologies (Wolters Kluwer Health). doi:10.1097/00000542-200407000-00021.
~8 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top